HCV Treatment
Novel P7 Inhibitor BIT225 Improves Hepatitis C Response, also Inhibits HIV
- Details
- Category: HCV Treatment
- Published on Friday, 16 December 2011 00:00
- Written by Press Release
At the HepDART drug development conference this month researchers presented interim data from a Phase 2 clinical trial showing that a novel direct-acting antiviral known as BIT225 improved the likelihood of virological response at 12 weeks when added to pegylated interferon/ribavirin.
Merck and Roche to Collaborate on Combination Regimens for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 16 December 2011 00:00
- Written by Press Release
Merck this week announced a collaboration with Roche to evaluate combination regimens for chronic hepatitis C virus (HCV) infection containing Merck's approved HCV protease inhibitor boceprevir (Victrelis) and Roche's experimental HCV polymerase inhibitor mericitabine (formerly RO5024048 and RG7128).
Two New Nucleotide HCV Polymerase Inhibitors Enter Clinical Trials
- Details
- Category: HCV Treatment
- Published on Tuesday, 13 December 2011 00:00
- Written by Press Release
A pair of hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitors, ALS-2200 and ALS-2158, are now entering Phase 1 human trials, according to a recent announcement.
Green Tea Component May Help Prevent HCV Re-infection after Liver Transplant
- Details
- Category: HCV Treatment
- Published on Tuesday, 13 December 2011 00:00
- Written by Liz Highleyman
An anti-oxidant compound in green tea may inhibit entry of hepatitis C virus (HCV) into liver cells, which could potentially prevent re-infection of the new liver after transplantation, according to a study described in the December 2011 issue of Hepatology.
New Hepatitis C NS5A Inhibitor ACH-2928 Shows Potent Antiviral Activity
- Details
- Category: HCV Treatment
- Published on Friday, 09 December 2011 00:00
- Written by Press Release
Achillion's novel once-daily hepatitis C virus (HCV) NS5A inhibitor ACH-2928 was well-tolerated and lowered viral load by more than 3.6 log in a 3-day monotherapy study, the company announced this week. These findings suggest ACH-2928 may be a promising candidate for inclusion in future oral direct-acting antiviral regimens.
More Articles...
- AASLD 2011: High Sustained Response Rates with Danoprevir plus Pegylated Interferon/Ribavirin for HCV
- HCV Polymerase Inhibitor INX-189 Looks Promising in Early Study
- AASLD 2011: Milk Thistle Extract Did Not Improve Liver Inflammation or Quality of Life for Hepatitis C Patients
- AASLD 2011: Daclatasvir with Pegylated Interferon/ Ribavirin Produces High Rates of HCV Suppression
Web Design and Development by